Cargando…

Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study

OBJECTIVE: Fosinopril and amlodipine are commonly prescribed as first-line pharmacotherapeutic agents for pediatric hypertension, but there is a lack of comparative studies regarding the efficacy of these two drugs. We aimed to evaluate and compare the efficacy of fosinopril and amlodipine monothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Shi, Lin, Lin, Yao, Wang, Yuting, Niu, Wenquan, Li, Yaqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641687/
https://www.ncbi.nlm.nih.gov/pubmed/37964810
http://dx.doi.org/10.3389/fped.2023.1247192
_version_ 1785146810349649920
author Wang, Hui
Shi, Lin
Lin, Yao
Wang, Yuting
Niu, Wenquan
Li, Yaqi
author_facet Wang, Hui
Shi, Lin
Lin, Yao
Wang, Yuting
Niu, Wenquan
Li, Yaqi
author_sort Wang, Hui
collection PubMed
description OBJECTIVE: Fosinopril and amlodipine are commonly prescribed as first-line pharmacotherapeutic agents for pediatric hypertension, but there is a lack of comparative studies regarding the efficacy of these two drugs. We aimed to evaluate and compare the efficacy of fosinopril and amlodipine monotherapy in pediatric primary hypertension. METHODS: This was a single-center, bidirectional observational study. A total of 175 children and adolescents with primary hypertension receiving antihypertensive monotherapy from July 2020 to February 2023 were enrolled. According to antihypertensive drugs, they were divided into the fosinopril group (n = 96) and the amlodipine group (n = 79). Subgroup analysis was performed to compare the efficacy of the two groups in terms of blood pressure (BP) control rates and reductions following a 4-week treatment. RESULTS: After 4 weeks of treatment, both groups achieved significant reductions in systolic BP (SBP) and diastolic BP (DBP) by more than 18 mmHg and 6 mmHg, respectively, with BP control rates of 61.5% in the fosinopril group and 59.5% in the amlodipine group, revealing no significant differences in the antihypertensive efficacy between the two groups except for DBP control rate (FDR adjusted P > 0.05). Further subsequent subgroup analyses revealed that the reductions in SBP and DBP in the fosinopril group were significantly greater than those in the amlodipine group in patients of females and hypo-HDL-cholesterolemia (FDR adjusted P < 0.05), and there was a trend of difference, although not significant, in patients with central obesity and insulin resistance (IR) (FDR adjusted 0.05 < P ≤ 0.1). However, there were no significant differences in treatment efficacy in patients without these characteristics. Furthermore, hypertriglyceridemia did not exhibit a significant association with the difference in treatment efficacy between the two medications (FDR adjusted P > 0.05). CONCLUSIONS: Fosinopril and amlodipine monotherapy were both effective in pediatric primary hypertension during a short-term follow-up. Fosinopril may be particularly effective in reducing BP in hypertensive patients of females, central obesity, IR, and hypo-HDL-cholesterolemia. These findings indicate that optimizing antihypertensive medication selection based on the individualized characteristics of children with hypertension may improve the efficacy of antihypertensive treatment.
format Online
Article
Text
id pubmed-10641687
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106416872023-11-14 Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study Wang, Hui Shi, Lin Lin, Yao Wang, Yuting Niu, Wenquan Li, Yaqi Front Pediatr Pediatrics OBJECTIVE: Fosinopril and amlodipine are commonly prescribed as first-line pharmacotherapeutic agents for pediatric hypertension, but there is a lack of comparative studies regarding the efficacy of these two drugs. We aimed to evaluate and compare the efficacy of fosinopril and amlodipine monotherapy in pediatric primary hypertension. METHODS: This was a single-center, bidirectional observational study. A total of 175 children and adolescents with primary hypertension receiving antihypertensive monotherapy from July 2020 to February 2023 were enrolled. According to antihypertensive drugs, they were divided into the fosinopril group (n = 96) and the amlodipine group (n = 79). Subgroup analysis was performed to compare the efficacy of the two groups in terms of blood pressure (BP) control rates and reductions following a 4-week treatment. RESULTS: After 4 weeks of treatment, both groups achieved significant reductions in systolic BP (SBP) and diastolic BP (DBP) by more than 18 mmHg and 6 mmHg, respectively, with BP control rates of 61.5% in the fosinopril group and 59.5% in the amlodipine group, revealing no significant differences in the antihypertensive efficacy between the two groups except for DBP control rate (FDR adjusted P > 0.05). Further subsequent subgroup analyses revealed that the reductions in SBP and DBP in the fosinopril group were significantly greater than those in the amlodipine group in patients of females and hypo-HDL-cholesterolemia (FDR adjusted P < 0.05), and there was a trend of difference, although not significant, in patients with central obesity and insulin resistance (IR) (FDR adjusted 0.05 < P ≤ 0.1). However, there were no significant differences in treatment efficacy in patients without these characteristics. Furthermore, hypertriglyceridemia did not exhibit a significant association with the difference in treatment efficacy between the two medications (FDR adjusted P > 0.05). CONCLUSIONS: Fosinopril and amlodipine monotherapy were both effective in pediatric primary hypertension during a short-term follow-up. Fosinopril may be particularly effective in reducing BP in hypertensive patients of females, central obesity, IR, and hypo-HDL-cholesterolemia. These findings indicate that optimizing antihypertensive medication selection based on the individualized characteristics of children with hypertension may improve the efficacy of antihypertensive treatment. Frontiers Media S.A. 2023-10-27 /pmc/articles/PMC10641687/ /pubmed/37964810 http://dx.doi.org/10.3389/fped.2023.1247192 Text en © 2023 Wang, Shi, Lin, Wang, Niu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Wang, Hui
Shi, Lin
Lin, Yao
Wang, Yuting
Niu, Wenquan
Li, Yaqi
Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title_full Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title_fullStr Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title_full_unstemmed Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title_short Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
title_sort efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641687/
https://www.ncbi.nlm.nih.gov/pubmed/37964810
http://dx.doi.org/10.3389/fped.2023.1247192
work_keys_str_mv AT wanghui efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy
AT shilin efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy
AT linyao efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy
AT wangyuting efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy
AT niuwenquan efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy
AT liyaqi efficacyoffosinoprilandamlodipineinpediatricprimaryhypertensionasinglecenterobservationalstudy